Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

Final appraisal determination

Final appraisal determination document (PDF 509 KB)

Public committee slides (PDF 473 KB)

Draft guidance: 2

Appraisal consultation document (PDF 544 KB)

Committee papers (PDF 977 KB)

Appeal

Pfizer Ltd : Appeal letter (PDF 525 KB)

Pfizer Ltd : Scrutiny letter (PDF 428 KB)

Pfizer Ltd : Response to scrutiny letter (PDF 226 KB)

Pfizer Ltd : Final scrutiny letter (PDF 403 KB)

Leukaemia CARE : Appeal letter (PDF 251 KB)

Leukaemia CARE : Scrutiny letter (PDF 410 KB)

Leukaemia CARE : Response to scrutiny letter (PDF 78 KB)

Leukaemia CARE : Final scrutiny letter (PDF 341 KB)

Jointly appealing: Royal College of Pathologists, Royal College of Physicians and the Association of Cancer Physicians : Appeal letter (PDF 182 KB)

Jointly appealing: Royal College of Pathologists, Royal College of Physicians and the Association of Cancer Physicians : Scrutiny letter (PDF 371 KB)

Jointly appealing: Royal College of Pathologists, Royal College of Physicians and the Association of Cancer Physicians : Response to scrutiny letter (PDF 237 KB)

Jointly appealing: Royal College of Pathologists, Royal College of Physicians and the Association of Cancer Physicians : Final scrutiny letter (PDF 349 KB)

Final appraisal determination

Final appraisal determination document (PDF 432 KB)

Committee papers (PDF 2.86 MB)

Draft guidance

Appraisal consultation document (PDF 393 KB)

Public committee slides Clinical (PDF 250 KB)

Public committee slides Cost (PDF 146 KB)

Final scope (PDF 262 KB)

Final matrix (PDF 303 KB)

NICE's response to comments on the draft scope and provisional matrix (PDF 412 KB)

Draft scope (post-referral) (PDF 267 KB)